The components of TAF/FTC and TDF/FTC have activity against hepatitis B virus (HBV). When persons with chronic HBV infection are prescribed TDF/FTC or TAF/FTC, these agents will also have an effect on ...
A Prescription Drug User Fee Act target date of June 19, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted under Priority Review the New Drug Application (NDA) ...
People living with HIV represent a unique population in the field of infectious disease and immunology due to persistent immune dysregulation and an ...
The US HIV/AIDS Strategy and Ending the HIV Epidemic (EHE) initiatives aim to reduce HIV transmission by 90% by 2030 through targeted care and prevention initiatives such as the Undetectable = ...
Alert Single Patient Shows Baraclude May Be Linked to Risk for Resistant HIV The warning is based on the development of an HIV variant strain in a single HIV/HBV-coinfected patient receiving entecavir ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for ...
A new formulation of Gilead’s HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection. This article first appeared in The Checkup, MIT Technology Review’s weekly biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results